Nexalin Technology, Inc. is a medical device company. It engaged in design and development of neurostimulation products for mental health epidemics. It has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. It also operates PONM, which is a digital health platform.
Company Information
About this company
Key people
Key facts
- Shares in issue829,399.00
- EPICNXL
- ISINUS65345B3006
- LocationUnited States
- SectorHealthcare
- IndustryMedical Equipment & Supplies
- Market cap$1.95m
- Employees8
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.